Mechanisms of resistance to sotorasib in lung cancer identified March 17, 2023 Oncology – First approved inhibitor once morest the KRAS oncogene. First approved inhibitor once morest the KRAS oncogene. Tumor cells rapidly adapt to the drug by increasing the number of copies of the mutated KRAS targeted by therapy. Sotorasib-resistant lung cancer cells carrying multiple copies of the mutated KRAS gene (in red). Photo: CICANCER. Share this: Share on Facebook (Opens in new window) Facebook Share on X (Opens in new window) X Alexandra Hartman Editor-in-Chief Editor-in-Chief Prize-winning journalist with over 20 years of international news experience. Alexandra leads the editorial team, ensuring every story meets the highest standards of accuracy and journalistic integrity.
